Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Current Assets (2016 - 2026)

Insight Molecular Diagnostics' Current Assets history spans 7 years, with the latest figure at $15.3 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 30.16% to $15.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.3 million, a 30.16% increase, with the full-year FY2025 number at $15.3 million, up 30.16% from a year prior.
  • Current Assets hit $15.3 million in Q4 2025 for Insight Molecular Diagnostics, down from $21.4 million in the prior quarter.
  • Over the last five years, Current Assets for IMDX hit a ceiling of $62.8 million in Q1 2021 and a floor of $4.8 million in Q3 2024.
  • Historically, Current Assets has averaged $26.6 million across 5 years, with a median of $23.0 million in 2022.
  • Biggest five-year swings in Current Assets: tumbled 71.67% in 2024 and later surged 454.9% in 2025.
  • Tracing IMDX's Current Assets over 5 years: stood at $39.1 million in 2021, then tumbled by 34.76% to $25.5 million in 2022, then crashed by 58.11% to $10.7 million in 2023, then rose by 9.92% to $11.8 million in 2024, then surged by 30.16% to $15.3 million in 2025.
  • Business Quant data shows Current Assets for IMDX at $15.3 million in Q4 2025, $21.4 million in Q3 2025, and $26.8 million in Q2 2025.